MGNX MACROGENICS INC


$ 1.66 $ -0.04 (-2.37 %)    

Friday, 17-Oct-2025 15:59:58 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ na
$ 1.68
$ 1.52 x 2,015
$ 1.80 x 1
$ 1.64 - $ 1.74
$ 0.99 - $ 5.10
464,528
na
104.29M
$ 1.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 macrogenics-forged-a-zynyz-royalty-purchase-deal-with-sagard-healthcare-partners-for-70m-upfront-payment-extending-cash-runway-through-first-half-of-2027

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing a...

 b-riley-securities-maintains-neutral-on-macrogenics-lowers-price-target-to-3

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target fr...

 stifel-maintains-hold-on-macrogenics-lowers-price-target-to-5

Stifel analyst Stephen Willey maintains Macrogenics (NASDAQ:MGNX) with a Hold and lowers the price target from $6 to $5.

 barclays-maintains-overweight-on-macrogenics-lowers-price-target-to-3

Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $8 to $3.

 macrogenics-q1-eps-065-beats-076-estimate-sales-1319m-beat-617m-estimate

Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.76) b...

 hc-wainwright--co-maintains-neutral-on-macrogenics-lowers-price-target-to-2

HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target ...

 jmp-securities-downgrades-macrogenics-to-market-perform

JMP Securities analyst Silvan Tuerkcan downgrades Macrogenics (NASDAQ:MGNX) from Market Outperform to Market Perform.

 hc-wainwright--co-reiterates-neutral-on-macrogenics-maintains-4-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.

 macrogenics-q3-eps-090-beats-021-estimate-sales-11071m-beat-7611m-estimate

Macrogenics (NASDAQ:MGNX) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.21 by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION